Aging Cognition Evaluation A Unique Opportunity in understanding age related disorders.

Slides:

Advertisements

Similar presentations

Combining neuropsychology and genetics in the study of mood disorders Daniel Smith MRCPsych Division of Psychiatry, University of Edinburgh Specialist.

Advertisements

The Diabetic Retinopathy Clinical Research Network

The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing AUSTRALIAN ADNI. July 2010 UPDATE.

December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.

Methods of collecting biological data: Considerations, challenges and implications ESRC Research Methods Festival 2012.

PRoBaND Parkinson’s Repository of Biosamples and Networked Datasets History Hypotheses Overview Linkage to other studies Funded by Parkinson’s UK Dr Donald.

High resolution clinical phenotype: Demographics Socio-Economic status Birth History Social History Family History Pre-kidney disease H. Kidney disease.

Tony WAEGEMANS, MD UCB Pharma, Belgium. TW/ll/ Washington/MCI 2 MCI as implemented in our study MCI is a very early stage of dementia with as main.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

CSF sulfatide is decreased in individuals with incipient dementia Xianlin Han, PhD, Anne M. Fagan, PhD, Hua Cheng, MS, John C. Morris, MD, Chengjie Xiong,

Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)

Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.

ACT on Alzheimer’s Disease Curriculum Module VII: Disease Diagnosis.

MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.

GAL-INT-6 The safety and efficacy of galantamine in patients with Vascular dementia or AD with cerebrovascular disease Sean Lilienfeld MD, FCP, MMed Janssen.

Screening for Stroke and Cognitive Impairment Chapter 2: Background.

Genetic Counseling By: Cary Edmondson ISAT 351 April 19, 1999.

Alzheimer’s Assessment Assessing the Cognitive-Linguistic effects of Alzheimer’s.

Updated on December 2 nd, 2008 Information about the BH4 and PKU Research Opportunity Sponsored by: Singh Research Group Emory University Department of.

Mary E. Crump, RN,MSN,MPH Clinic Manager – Jackson Heart Study Clinic.

Epidemiology of Dementia: the MoVIES Project Alzheimer’s Disease Patient Registry (ADPR ), University of Pittsburgh Initially funded by NIA under.

VAMC/ST LOUIS UNIVERSITY

A Program of Research Examining the Cognitive Correlates of Methamphetamine Abuse.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.

The Diabetic Retinopathy Clinical Research Network

Procedures Manual, Control Series, & Phenotype Committee Update Stephanie Doan, MPH NIA AD Genetics Initiative Co-Coordinator Columbia University.

2008© COPYRIGHT Thrombosis and Hemostasis Centers Research and Prevention Network Centers for Disease Control & Prevention Thomas L. Ortel, M.D., Ph.D.

Project CLASS “Children Learning Academic Success Skills” This work was supported by IES Grant# R305H to David Rabiner Computerized Attention Training.

Laurence Lacoste Ph. D, Paris, France 1*. Introduction : Why ?  Population’s Ageing is a Public Health issue and dementia for the Elderly a reality 

Assessing and Counseling Older Drivers Identifying and Assessing the Medically Impaired Driver.

Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP

MRI as a Potential Surrogate Marker in the ADCS MCI Trial

A step-by-step guide to help you determine if your research protocol is required to be reviewed by the Lindenwood University IRB INSTITUTIONAL REVIEW BOARD.

· Lecture 31 & 32 : Scope of clinical biochemistry ط Uses of clinical biochemistry tests ط Diagnosis, Prognosis, Screening, Monitoring ط Reporting results.

Are spatial tasks useful for the early diagnosis of Alzheimer’s disease.

Part C Eligibility (Part H). Eligibility Criteria: Children ages birth through two who are developmentally delayed or are at established risk for developmental.

Which factors predict outcome in the nonoperative treatment of patellofemoral pain syndrome? A prospective follow-up study Kannus P, Nittymaki S. Med.

An Innovative Approach to Fair Evaluations for People with Cognitive Disabilities.

THE MURDOCK Study: A Rich Data Resource for Biomarker Discovery and Validation Brian D. Bennett 1, Jessica D. Tenenbaum 1, Victoria Christian 1, Melissa.

NHS Health Checks Helping you prevent heart disease, stroke, diabetes and kidney disease.

Child Psychopathology Diagnosis Treatment Reading for today: Chapter 4.

Background. Vascular Cognitive Impairment Vascular Cognitive Impairment (VCI) includes the cognitive and behavioural disorders associated with cerebrovascular.

Virtual ACE Update.

Identifying and Tracking Changes in Cognition Related to NPH Sheldon Herring, Ph.D. Clinical Director Outpatient Brain Injury and Young Stroke Program.

Cancer 101: A Cancer Education and Training Program for American Indians & Alaska Natives Cancer 101: A Cancer Education and Training Program for American.

Kimiko Domoto-Reilly, MD Cognitive / Behavioral Neurology Fellow Massachusetts General Hospital & Brigham and Women’s Hospital.

Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.

Challenges facing biomedicine Data handling and mining Redefining disease Therapeutics.

Mild Cognitive Impairment, Activity Participation, Functional Difficulty, and Adaptations in Functionally Vulnerable Elderly People: A Closer Look Laraine.

The Royal College of Emergency Medicine The Royal College of Emergency Medicine Clinical Audits Initial management of the fitting child Clinical Audit.

Comparison of Risk Factors for Early-Onset versus Late-Onset Alzheimer Disease OBJECTIVE To compare early-onset (before 65) Alzheimer disease (AD) patients.

Circulation. 2014;129: Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy.

Results Results Dillon C, MD, PhD; Vazquez G, MD, PhD ; Corrales A, MD; Allegri RF, MD, PhD; Taragano FE, MD, PhD. CEMIC University Hospital, SIREN, Department.

The Natural History of Benign Thyroid Nodules JAMA. 2015;313(9): doi: /jama Modulator Prof. 전숙 / R1 윤수진.

1 Screening Mental Health In Primary Care: Cradle to Grave Toolkit Mary R. Talen, Ph.D. Director, Behavioral Health Science MacNeal Family Medicine Berwyn,

RESEARCH & INNOVATION SHOWCASE Dr Lauren Walker MRC Clinical Training Fellow supported by the North West England MRC Fellowship Scheme in Clinical Pharmacology.

Myotonic Dystrophy Research: What’s Next

Aka STEEL VALLEY SENIORS SURVEY (SVSS)

بايو كمستري (م 3) / د . احمد الطويل

GLUCOSE TOLERANCE TEST (GTT)

CORRELATION OF BIOMARKERS FOR AXONAL DEGENERATION WITH RETINAL NERVE FIBER LAYER THICKNESS AND DISABILITY IN DIFFERENT PHASES OF MULTIPLE SCLEROSIS UZUNKOPRU.

Epidemiology of Dementia: the MoVIES Project

Analysis of diagnostic studies: defining the questions, study phases, and designs P.G. Duca, D. Prati.

ADI Disease International 7-10 March, 2012

PPMI – GOALS 2019 Ken Marek PPMI Annual Meeting May 3, 2018

Changes in cerebrospinal fluid magnesium levels in patients undergoing spinal anaesthesia for hip arthroplasty: does intravenous infusion of magnesium.

*****For more information, please call*****

Understanding the Nature of Sleep and How it Changes With Age

Statistically-Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile AnalysiS.

Background of PI Name: Wen-Yih Isaac Tseng, MD, PhD

Presentation transcript:

Aging Cognition Evaluation A Unique Opportunity in understanding age related disorders

u Improve understanding of the biology of memory disorder with concurrently collected serial: u Cognitive data u Biological samples u Clinical events u Potential applications across other pathologies u Discover predictive biomarkers

u Establish robust baseline cognition score u Identify meaningful changes in cognition u Follow cognition deficits and rate of change u Correlate changes in cognition score with changes in biology u Identify well characterized patients for further evaluation Objectives

BIOLOGICAL u Genomic DNA u RNA from PAXGene u PBMCs ~4ml u Serum 0.5ml u Plasma 0.5ml u Urine 5ml u CSF 0.5ml (subpopulation) PSYCHOMETRIC u Semantic memory u Working memory u Executive function u Concentration u Response speed u MMSE DEMOGRAPHIC u Family History u Current Meds u Ethnic History u Education u Smoking u Alcohol u Clinical events Outputs

u 6-monthly serial follow-up of up to 5000 healthy subjects >60 y/o. u Collection of biological fluid samples including CSF (subpopulation) with simultaneous clinical and cognition evaluations using a CDR cognition battery at each 6 monthly visit. Protocol

The ACE Solution: identify MCI using… …evidence of progressive cognitive decline

6 Monthly report to subject

Protocol design Age Able to present for a blood draw every 6 months Generally healthy Cognitively normal Consent CDR Cognition Battery training Con Meds Con Diagnoses Family history ECG Other tests Cognition Battery Con Meds Con Diagnoses Blood Draw Spinal Tap (subpopulation) Cognition Battery Con Meds Con Diagnoses Blood Draw Spinal Tap (subpopulation) 6 months Controls Cognition diminished SCR.V.1 V.2 Cognition normal

ActivityScreening Visit Visit 1 BASELINE Subsequent 6 Monthly Visits Informed consent document signed X Subject and Visit Identification XXX DemographicsX Subject/Family historyXXX Concomitant Medications XXX Overnight fastXX Blood/urine Sample for banking XX Optional Spinal Tap for banking XX CDR Cog. Battery, MMSE X**XX Medication change since previous visit XX Clinical events since previous visit XX * Subpopulation ** Training Protocol design Contd: